Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients by Spyridonidis, A. et al.
Bone Marrow Transplantation (2020) 55:1114–1125
https://doi.org/10.1038/s41409-020-0803-y
ARTICLE
Redefining and measuring transplant conditioning intensity
in current era: a study in acute myeloid leukemia patients
This article has been corrected since Advance Online Publication and a correction is also printed in this issue
Alexandros Spyridonidis 1 ● Myriam Labopin2 ● Bipin N. Savani 3 ● Riitta Niittyvuopio4 ● Didier Blaise 5 ●
Charles Craddock6 ● Gerard Socié 7 ● Uwe Platzbecker8 ● Dietrich Beelen9 ● Noel Milpied10 ● Jan J. Cornelissen11 ●
Arnold Ganser12 ● Anne Huynh13 ● Laimonas Griskevicius14 ● Sebastian Giebel15 ● Mahmoud Aljurf16 ● Eolia Brissot2 ●
Florent Malard 2 ● Jordi Esteve17 ● Zinaida Peric18 ● Frédéric Baron19 ● Annalisa Ruggeri20 ● Christoph Schmid21 ●
Maria Gilleece 22 ● Norbert-Claude Gorin2 ● Francesco Lanza23 ● Roni Shouval24 ● Jurjen Versluis12 ● Gesine Bug25 ●
Yngvar Fløisand26 ● Fabio Ciceri27 ● Jamie Sanz 28 ● Ali Bazarbachi29 ● Arnon Nagler30 ● Mohamad Mohty2
Received: 10 October 2019 / Revised: 30 November 2019 / Accepted: 16 January 2020 / Published online: 29 January 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2020
Abstract
To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme
we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell
transplantation (HCT). We assigned intensity weight scores for frequently used conditioning regimen components and used
their sum to generate the transplant conditioning intensity (TCI) score. We retrospectively tested the impact of TCI on 8255
adult (45–65 years) acute myeloid leukemia patients who underwent HCT in first complete remission. A Cox model for early
nonrelapse mortality (NRM) yielded a 3-group TCI risk scheme (low, intermediate, high) with respective TCI scores of
[1–2], [2.5–3.5] and [4–6]. On multivariate modeling, TCI grouping was highly and better predictive for early (day 100 and
180) NRM, 2-year NRM and relapse (REL) as compared with the RIC/MAC classification. Validation was done on 200
bootstrap samples. Moreover, TCI scoring enabled the identification of a distinct subgroup of RIC and MAC conditioning
regimens with an intermediate TCI [2.5–3.5] score that had identical outcomes and which are frequently referred as “reduced
toxicity conditioning”. TCI scheme provides an improvement of the RIC/MAC classification. We propose TCI as a new tool
to define and measure the conditioning regimen intensity.
Introduction
The pre-transplantation conditioning regimen plays a
central role in allogeneic hematopoietic cell transplanta-
tion (HCT) since it is essential for the engraftment of the
infused graft [1]. Nowadays, a lot of conditioning regi-
mens exist which fulfill this requirement but differ sub-
stantially in their intensity profile. The latter characteristic
is directly related to early morbidity, nonrelapse mortality
(NRM) and long term disease control. Transplant regi-
mens were initially categorized by their intensity as
“standard” myeloablative conditioning (MAC) and
reduced-intensity conditioning (RIC) or nonmyeloablative
(NMA) based on the expected duration of the pancyto-
penia (irreversible, prolonged, minimal) and on the
requirement for stem cell support (essential, required,
optional) [2–4]. Since these criteria are rather vague, the
European Society for Blood and Marrow Transplantation
(EBMT) [5] and the Center for International Blood and
Marrow Transplant Research (CIBMTR) [6] proposed in
2009 operational definitions for stratification of transplant
conditioning as MAC or RIC based on the total dose of
the alkylating agents and/or total body irradiation (TBI)
used. Briefly, RIC usually includes a purine analog and an
alkylating agent or TBI at a dose which is generally
reduced by at least ≥30% of the classical MAC regimens
[7, 8]. The RIC/MAC classification model has served as a
reliable clinical tool offering safer transplantation in older
and unfit patients and is widely referenced in the scientific
literature, but has never been updated or more precisely
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defined though transplantation practices change and new
conditionings are now used.
The limitations of the current RIC/MAC classification
scheme in the current era are exemplified by the arbitrary
use of terms such as “reduced toxicity conditioning” or
“sequential conditioning” by many authors [9, 10]. Novel
drugs (e.g., thiotepa and optimized forms of drugs e.g.,
treosulfan) with reduced nonhematological toxicity are
frequently used nowadays and their different toxicity pro-
files are not considered in the current RIC/MAC classifi-
cation scheme [11, 12]. RIC/MAC operational rules ignore
the additional intensity of purine analogs used for immu-
noablation (e.g., fludarabine, clofarabine) or of disease-
specific drugs used to achieve reduction in relapse risk (e.g.,
cytarabine, etoposide), and thus important prognostic
information is lost [13].
Therefore, we sought to develop a tool that can define
and standardize the intensity of a conditioning regimen
more effectively than existing nomenclature. We assigned
intensity weight scores for frequently used conditioning
regimen components and used the sum of the individual
weights to generate the Transplant Conditioning Intensity
(TCI) score. In the present study, we retrospectively tested
the TCI in a large cohort of adult acute myeloid leukemia
(AML) patients and compared it with the standard RIC/
MAC stratification scheme in predicting outcomes.
Materials and methods
TCI score development
Components for which the myeloablative doses are defined
by the EBMT [5] and/or CIBMTR [6] (TBI, busulfan,
melphalan, treosulfan and thiotepa) were assigned one of
three dose intensity levels by using the threshold myeloa-
blative dose as the intermediate dose level and assigning all
doses below or above to the low or high dose level,
respectively. For each of these components, we assigned a
weighted score of 1 for the lower dose and an extra point for
every dose level, except for thiotepa which was assigned an
added weighted score of 0.5 for each level because of its
reduced nonhematological toxicity [11]. Components for
which a “myeloablative dose” definition does not exist,
such as purine analogs, carmustine, etoposide and cytar-
abine, were considered in terms of the dose ranges used in
practice and were assigned an additional weight of 0.5 for
each dose level. An international expert panel (listed in
authorship) participated in a workshop organized by the
Acute Leukemia Working Party (ALWP) of the EBMT and
provided scientific and clinical guidance for the TCI score
development. Agents and their integer weights are shown in
Table 1. The TCI score for a specific conditioning regimen
is based on the sum of the weights for each component
given any day before the graft infusion.
Transplant data
This was a retrospective multicenter analysis. Data were
provided by the ALWP of the EBMT registry in which >
500 transplant centers report annually all consecutive HCTs
after patient’s authorization via informed consent and
approval of the study from ALWP EBMT general assembly.
We focused on patients aged between 45 and 65 years with
a diagnosis of AML (de novo or secondary) who had
received an allogeneic HCT at first complete remission (less
than 5% bone marrow [BM] blasts at transplant). Other
inclusion criteria included time from diagnosis to HCT <
18 months, transplant between 2005 and 2017, peripheral
blood stem cell (PBSC) or BM graft from a matched sibling
Table 1 Intensity weighted
scores for common components
included in transplantation
conditioning regimens.
Component Dose level Added points for
each dose level
Low Intermediate High
TBI fractionated (Gray) ≤5 6–8 ≥9 1
Busulphan (mg/kg) ≤6.4 iv & ≤8 po 9.6 iv & 12 po 12.8 iv & 16 po 1
Treosulfan (g/m2) 30 36 42 1
Melphalan (mg/m2) <140 ≥140 ≥200 1
Thiotepa (mg/kg) <10 ≥10 ≥20 0.5
Fludarabine (mg/m2) ≤160 >160 0.5
Clofarabine (mg/m2) ≤150 >150 0.5
Cyclophosphamide (mg/kg) <90 ≥90 0.5
Carmustine (mg/m2) ≤250 280–310 ≥350 0.5
Cytarabine (g/m2) <6 ≥6 0.5
Etoposide (mg/kg) <50 ≥50 0.5
iv intravenously, po per os, TBI total body irradiation.
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donor (MSD) or 9–10/10 HLA-matched unrelated donor
(MUD) and availability of detailed conditioning informa-
tion. MAC or RIC status was reported by the transplant
centers according to EBMT operational definitions [5] and
guidelines (MED-AB Manual, 31/1/2018) and was recon-
firmed for every patient.
Statistical analysis
Early nonrelapse mortality (NRM) at day (d) 180 was used
as the first endpoint for estimating the impact of TCI.
Results of NRM at d 100 were also given as this endpoint is
often reported in the literature. Secondary endpoints inclu-
ded NRM and relapse incidence (REL) at 2 years, overall
survival (OS) and leukemia-free survival (LFS). A grouping
scheme based on TCI score was created by merging the
underrepresented scores (< 30 patients) with contiguous
scores. A Cox proportional hazards model for NRM at day
180 including the TCI score as an ordered variable was used
to merge the classes that did not improve the likelihood of
the model, using a p value of 0.10. Univariate analyses were
performed using the Gray’s test for cumulative incidence
functions (NRM, REL) and the log-rank test for OS and
LFS. Patient, disease, and transplant-related characteristics
for the TCI groups were compared using the χ2 statistic for
categorical variables and the Kruskal–Wallis test for con-
tinuous variables. All variables differing significantly (p <
0.05) between the TCI groups or factors known to be
relevant from the literature were included in the final Cox
model. Internal validation of models was performed using
the bootstrap resampling method [14]. The model was
refitted for each of the 200 bootstrap samples. Confidence
intervals of c-statistics using either TCI or RIC/MAC
categorization were estimated from the 200 bootstrap sam-
ples and used to calculate a p value for the difference, using
the paired t-test. Statistical analyses were performed with
SPSS 24.0 (SPSS Inc., Chicago, IL, USA) and R 3.4.0
(R Core Team 2017. R Foundation for Statistical Comput-
ing, Vienna, Austria. URL: https://www.R-project.org/).
Results
Patient and transplant characteristics
The patient and transplant characteristics of the 8255 AML
patients (median age 55.6 years, range 45–65) are shown in
Table 2. All patients were transplanted in first complete
remission. The conditioning regimens used are listed in
Supplementary Table 1 and comprised RIC in 61% and
MAC in 39% of the patients (Fig. 1a). Acute graft-versus-
host disease (GVHD) II-IV occurred in 17.2% (95% con-
fidence interval [CI]: 16.3–18.1), acute GVHD III-IV in
8.2% (95% CI: 7.7–8.9), chronic GVHD in 39.1% (95% CI:
38–40.3) and extensive chronic GVHD in 17.3% (95% CI:
16.4–18.2). The 2-year outcomes for the entire cohort were
as follows: NRM 17% (95% CI: 16.1–17.8), REL 26.7%
(95% CI: 25.7–27.7), LFS 56.4% (95% CI: 55.2–57.5) and
OS 61.6% (95% CI: 60.4–62.7). Causes of NRM are given
in Supplementary Table 2.
TCI scores
The TCI score ranged from 1 to 6 (median 2.5) with a
median of 2 (range, 1–5.5) in the RIC group and 4 (range,
2.5–6) in the MAC group (p < 0.001). Those scores relating
to very few patients were pooled with patient groups
assigned to subsequent or previous scores: 26 patients with
a TCI score of 1 were combined with patients with a score
of 1.5 while 42 patients with TCI scores > 4.5 (27, 13 and 2
patients with TCI scores 5.0, 5.5 and 6.0, respectively) were
combined with patients with a score equal to 4.5. After
merging TCI values that did not improve the likelihood of
the Cox model for NRM at d 180 (p ≥ 0.10), three TCI
groups (low, intermediate and high) were derived with
respective scores of [1,2], [2.5–3.5] and [4–6].
The distribution according to TCI score group was as
follows: 38% had a low [1, 2], 41% an intermediate
[2.5–3.5] and 21% a high [4–6] TCI score regimen
(Fig. 1a). Table 2 shows patient, disease and transplant
characteristics of TCI groups. Nearly all patients with a high
TCI score [4–6] regimen received MAC (94%) and all low
TCI [1,2] patients received RIC (100%), indicative of good
concordance between RIC/MAC and low/high TCI score
grouping. Notably, the intermediate TCI [2.5–3.5] group
included patients with MAC and RIC regimens in about the
same fraction (54 and 46%, respectively). As expected,
there was an inverse relationship between age and TCI
score with a median age of 58.1 years, 56.2 years and 50.7
years for the low, intermediate, and high TCI groups,
respectively (p < 0.001). Patients in the low TCI group were
more likely to have a low KPS and high HCT-CI (p <
0.0001). Graft failure was low and did not differ between
TCI groups (p= 0.68). Figure 1b shows the TCI score for
classical and commonly used conditioning regimens.
Performance of the TCI
In univariate analysis, d 100 and d 180 NRM for patients in
the low TCI [1,2] group was statistically different as com-
pared with intermediate TCI [2.5–3.5] (p < 0.0001) and high
TCI [4–6] group patients (p < 0.0001) (Table 3). Similar
results were found when patients between 45 and 55 years
of age (47% of the cohort) and 55–65 years of age (53% of
the cohort) were analyzed separately (Fig. 2) or when the
analysis was restricted to the group of patients (n= 220)
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Table 2 Patient and transplant characteristics.
Variable Entire cohort TCI [1,2] TCI [2.5–3.5] TCI [4–6] p value*
N (%) 8255 (100%) 3123 (37.8%) 3371 (40.8%) 1761 (21.3%)
Follow-up (months)
Median (IQR) 42.4 (18.7–76.2) 42.8 (19.6–76.6) 40.2 (18.7–72.7) 47.6 (16.6–82.1) 0.11
Age at HCT (years)









45–55 3858 (46.7%) 1018 (32.6%) 1444 (42.8%) 1396 (79.3%) <0.0001
≥55 4397 (53.3%) 2105 (67.4%) 1927 (57.2%) 365 (20.7%)
Year of HCT
Median (range) [IQR] 2013 (2005–2017) 2013 (2005–2017) 2013 (2005–2017) 2012 (2005–2017) <0.01
Time diagnosis to HCT
(months)










MAC 3203 (38.8%) 0 (0%) 1552 (46.0%) 1651 (93.7%) <0.0001
RIC 5052 (61.2%) 3123 (100%) 1819 (54.0%) 110 (6.2%)
Donor
MSD 4405 (53.4%) 1612 (51.6%) 1675 (49.7%) 1118 (63.5%) <0.0001
UD 10/10 3068 (37.2%) 1233 (39.5%) 1325 (39.3%) 510 (29.0%)
UD 9/10 782 (9.5%) 278 (8.9%) 371 (11.0%) 133 (7.6%)
Patient sex
Male 4318 (52.4%) 1596 (51.2%) 1762 (52.3%) 960 (54.7%) 0.06
Female 3927 (47.6%) 1524 (48.9%) 1607 (47.7%) 796 (45.3%)
Missing 10 3 2 5
Donor sex
Male 5042 (61.5%) 1896 (61.14%) 2100 (62.65%) 1046 (59.9%) 0.14
Female 3157 (38.5%) 1205 (38.9%) 1252 (37.35%) 700 (40.1%)
Missing 56 22 19 15
Sex matching
Not Female- >Male 6750 (82.1%) 2574 (82.9%) 2770 (82.34%) 1406 (80.4%) 0.09
Female- >Male 1470 (17.9%) 533 (17.2%) 594 (17.66%) 343 (19.6%)
Missing 35 16 7 12
Cytogenetics**
Good 220 (2.67%) 74 (2.4%) 94 (2.8%) 52 (3.0%) <0.0001
Interm 3479 (42.1%) 1541 (49.3%) 1372 (40.7%) 566 (32.1%)
Poor 1225 (14.8%) 490 (15.7%) 518 (15.4%) 217 (12.3%)
NA/failed 3331 (40.3%) 1018 (32.6%) 1387 (41.2%) 926 (52.6%)
Type of AML
de novo 6835 (82.8%) 2524 (80.8%) 2756 (81.8%) 1555 (88.3%) <0.0001
Secondary AML 1420 (17.2%) 599 (19.2%) 615 (18.2%) 206 (11.7%)
Source of stem cells
BM 894 (10.8%) 189 (6.1%) 386 (11.5%) 319 (18.11%) <0.0001
PBSC 7361 (89.2%) 2934 (94.0%) 2985 (88.6%) 1442 (81.9%)
KPS at HCT
<80 282 (3.6%) 151 (5.2%) 97 (3.0%) 34 (2.0%) <0.0001
≥80 7505 (96.4%) 2751 (94.8%) 3108 (97.0%) 1646 (98.0%)
Missing 468 221 166 81
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with good risk cytogenetics (d 180 NRM= 1.5%, 11.9%
and 14.6% in TCI [1,2], [2.5–3.5] and [4–6], respectively,
p= 0.02). TCI scores also predicted overall NRM and REL
with the differences being observed in both age groups
(Table 3). In multivariate analysis, there was a monotonic
increase in risk of early NRM with each TCI group from
low to high (Table 4). Patients in the intermediate TCI
regimen group had a significantly higher NRM at d 100
(HR 2.0; 95% CI, 1.54–2.59, p < 0.0001) and at d 180 (HR
1.63; 95% CI, 1.35–1.98, p < 0.0001) when compared with
the low TCI group. The HRs for d 100 and d 180 NRM in
patients receiving a high TCI [4–6] score regimen was 3.06
(95% CI, 2.24–4.16, p < 0.0001) and 2.31 (95% CI,
1.83–2.92, p < 0.0001) when compared with low TCI [4–6]
and 1.53 (95% CI, 1.19–1.97, p= 0.001) and 1.41 (95% CI,
1.15–1.73, p= 0.0008) when compared with the inter-
mediate TCI [2.5–3.5] group, respectively. TCI grouping
was also highly significantly associated with overall NRM
and REL (Table 4). Compared with low TCI group patients,
the relapse risk for patients receiving intermediate and high
score TCI regimens was significantly decreased with an HR
of 0.81 (95% CI, 0.73–0.89, p < 0.0001) and 0.70 (95% CI,
0.61–0.8, p < 0.0001), respectively. The HRs for NRM for
the intermediate (1.27; 95% CI, 1.12–1.44) and the high
TCI (1.44; 95% CI 1.22–1.69) groups also remained highly
predictive (p= 0.0003 and p < 0.0001 relative to the low
TCI group, respectively). We re-run the multivariable Cox
model in the patients with available HCT-CI information
(n= 4047, 50% of the entire cohort) and TCI remained
significantly associated with early NRM, NRM and REL
(Supplementary Table 3).
When the RIC/MAC categorization was used in the
multivariate model, RIC/MAC also predicted early NRM,
overall NRM and REL (Supplementary Table 4). In both
classification systems (TCI or RIC/MAC), early NRM was
also independently influenced by age, performance status
Table 2 (continued)
Variable Entire cohort TCI [1,2] TCI [2.5–3.5] TCI [4–6] p value*
<90 1680 (22.2%) 790 (28.2%) 632 (20.0%) 258 (15.9%) <0.0001
≥90 5899 (77.8%) 2007 (71.8%) 2524 (80.0%) 1368 (84.1%)
Missing 676 326 215 135
HCT-CI score
HCT-CI= 0 2305 (57.0%) 763 (52.5%) 1043 (55.8%) 499 (68.6%) <0.0001
HCT-CI= 1 or 2 881 (21.7%) 326 (22.5%) 422 (22.6%) 133 (18.3%)
HCT-CI ≥ 3 861 (21.3%) 363 (25%) 403 (21.6%) 95 (13.1%)
Missing 4208 1671 1503 1034
In vivo TCD
No 3459 (42.2%) 1344 (43.2%) 1099 (32.8%) 1016 (58.4%) <0.0001
Yes 4742 (57.8%) 1767 (56.8%) 2251 (67.2%) 724 (41.6%)
Missing 54 12 21 21
Patient CMV
CMV negative 2398 (29.5%) 1008 (32.7%) 970 (29.2%) 420 (24.5%) <0.0001
CMV positive 5727 (70.5%) 2078 (67.3%) 2353 (70.8%) 1296 (75.5%)
Missing 130 37 48 45
Donor CMV
CMV negative 3577 (44.5%) 1448 (47.3%) 1471 (44.7%) 658 (38.8%) <0.0001
CMV positive 4469 (55.5%) 1612 (52.7%) 1821 (55.3%) 1036 (61.2%)
Missing 209 63 79 67
Engraftment
Graft failure 114 (1.4%) 39 (1.3%) 50 (1.5%) 25 (1.4%) 0.68
Engrafted 8035 (98.2%) 3052 (98.4%) 3265 (98.1%) 1718 (98.3%)
Graft loss 30 (0.4%) 11 (0.4%) 15 (0.5%) 4 (0.2%)
Missing 76 21 41 14
AML acute myeloid leukemia, CMV cytomegalovirus, BM bone marrow, HCT allogeneic hematopoietic cell transplantation, HCT-CI HCT-
comorbidity index, IQR interquartile ration, KPS Karnofsky Performance Status, MAC myeloablative conditioning, MSD matched sibling donor,
NA not available, PBSC peripheral blood stem cells, RIC reduced-intensity conditioning, TCD T-cell depletion, TCI transplant conditioning
intensity score, UD unrelated donor.
*p values between TCI groups; **Cytogenetic risk according to MRC classification (Blood 2010;116:354–65).
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and donor and overall NRM was in addition predicted by
female to male transplant, in vivo T-cell depletion, year of
HCT and CMV serostatus (Table 4). Relapse associated
with secondary AML, poor cytogenetics, unrelated donor,
female to male transplant and a PBSC graft. On multivariate
analysis, neither LFS or OS were associated with con-
ditioning intensity stratified by TCI (Table 4) or RIC/MAC
status (Supplementary Table 4).
Validation of the TCI and comparison with RIC/MAC
The TCI continued to be strongly associated with early
NRM, overall NRM and REL on 200 bootstrap samples.
The predictive ability of the TCI estimated by c-statistics is
shown in Table 5. Compared with the model including RIC/
MAC with bootstrapping, the c-statistics for early and
overall NRM, REL, LFS and OS were significantly better
(p < 0.0001 for NRM, REL and LFS, p= 0.007 for OS).
The intermediate TCI [2.5–3.5] group
We focused on the intermediate TCI [2.5–3.5] group (n=
3371, median age 56.2 years) in which nearly half (54%) of
the patients had received MAC and the other 46% received
a RIC regimen (Fig. 1a). Within this group, the median TCI
score of RIC patients was 2.5 (range, 2.5–3.5) and of MAC
patients was 3.5 (range, 2.5–3.5) (p < 0.0001). In the uni-
variate analysis, d 100 NRM, d 180 NRM, overall NRM,
REL, LFS, and OS were not different between patients who
had received a TCI [2.5–3.5]-RIC or a TCI [2.5–3.5]-MAC
regimen (Table 6).
Discussion
Risk assessment for allogeneic HCT is based on scores and
indices developed specifically to measure comorbidity
burden (e.g., HCT-CI) [15], disease risk (e.g., DRI) [16] and
conditioning regimen intensity (RIC/MAC). As transplan-
tation practices change, these prognostic tools need to be
updated [17]. In this study, we evaluated a new tool for a
better and more standardized stratification of transplant
conditioning intensity, which we favor to replace the current
RIC/MAC classification scheme.
The TCI was developed in a way that refines the currently
used RIC/MAC classification system. We used the generally
accepted myeloablative threshold doses to define the middle
drug intensity [5, 6]. We incorporated in the TCI compo-
nents that are not considered in the current RIC/MAC
classification (purine analogs, cyclophosphamide, cytar-
abine, etoposide and carmustine), but we intentionally gave
them a lower integer weighting adhering to the RIC/MAC
consensus that these drugs add less to the regimen intensity
stratification. All of these agents have a well-documented
toxicity and antileukemic activity and thus it is very likely
that they influence NRM and REL [13]. Thus, TCI is gen-
erally based on consensus RIC/MAC definitions and can be
easily and reproducibly calculated for every regimen.
Although TCI scoring stratified the regimens on a con-
tinuum (Fig. 1b), it is unlikely that the clinical impact of









































Transplant condtioning  intensity score
Fig. 1 Distribution of conditioning regimes according to their
intensity. a The graphic shows the distribution of the conditioning
regimens used in 8255 patients with AML transplanted at first com-
plete remission according to their intensity. RIC/MAC is according to
EBMT definition. Transplant Conditioning intensity (TCI) score was
calculated for each individual transplant and was allocated to the low
TCI [1,2], intermediate TCI [2.5–3.5] or high TCI [4–6] group. b The
graphic shows the calculated TCI score for classical and commonly
used conditioning regimens. The different colors denote the different
TCI groups (green: low TCI [1,2], blue: intermediate TCI [2.5–3.5]
and red: high TCI [4–6]). TBI(12)/VP16/CY= 12 Gray TBI, Etopo-
side 50 mg/kg, Cyclophosphamide 60 mg/kg; TBI(12)/CY= 12 Gray
TBI, Cyclophosphamide 120 mg/kg; BuCy= Busulfan 4 days 3.2 mg/
kg/day IV or 4 mg/kg/day oral), Cyclophosphamide 120 mg/kg; Bu(4/
3/2)Flu= Busulfan 4,3,2 days, Fludarabine 90–150 mg/kg; FBM=
Fludarabine 120 mg/kg, Carmustine (BCNU) 300 mg/m2, Melphalan
110 mg/m2; FLAMSA= Fludarabine 120 mg/kg, Busulfan 2 days (or
TBI 4 Gray), Aracytine 8 g/m2, Cyclophosphamide 80 mg/kg and
Amsacrine 400 mg/m2; TBu(3/2)F= Busulfan 3/2 days, Thiotepa 5
mg/kg, Fludarabine 120–150 mg/kg; Treo36Flu= Treosulfan 36 mg/
m2, Fludarabine 120–150 mg/m2; FluMEL (140/110)= Fludarabine
90–150 mg/kg, Melphalan 110/140 mg/m2; FluTBI (2 Gy)= Fludar-
abine 90 mg/kg, TBI 2 Gray; FluTT= Fludarabine 90 mg/kg, Thiotepa
15 mg/kg; FluCy= Fludarabine 90–120 mg/kg, Cyclophosphamide
50 mg/kg.
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clinical relevance regarding early NRM, which yielded a 3-
group risk scheme. While a concordance between low/high
TCI and RIC/MAC groups was observed, the intermediate
TCI group, which captured nearly half of the patients,
included both RIC and MAC regimens in the same fraction
(Fig. 1a). Thus, TCI and the RIC/MAC grouping schemes
differ substantially from each other and can be used as
separate classification systems.
Table 3 Univariate analysis of transplant outcomes.
N NRM @ day100 NRM @ day180 NRM Relapse
Entire population
TCI [1,2] 3123 3.2% [2.6–3.8] 6.8% [6–7.8] 14.9% [13.6–16.3] 30.6% [28.9–32.3]
TCI [2.5–3.5] 3371 6.3% [5.6–7.2] 10.5% [9.5–11.6] 17.9% [16.6–19.3] 25.3% [23.7–26.8]
TCI [4–6] 1761 7.6% [6.5–8.9] 12% [10.5–13.6] 18.7% [16.8–20.7] 22.2% [20.2–24.3]
p value <0.0001 <0.0001 0.0001 <0.0001
RIC 5052 4.6% [4–5.2] 8.4% [7.6–9.2] 16.4% [15.3–17.5] 28.2% [26.9–29.5]
MAC 3203 6.8% [5.9–7.7] 11.2% [10.1–12.3] 17.9% [16.5–19.3] 24.1% [22.6–25.7]
p value <0.0001 <0.0001 0.23 <0.0001
45–55 years
TCI [1,2] 1018 2.8% [1.9–3.9] 6.1% [4.7–7.7] 13.4% [11.3–15.8] 30% [27.1–33]
TCI [2.5–3.5] 1444 4.9% [3.9–6.1] 8.1% [6.8–9.6] 14% [12.2–16] 24.3% [22–26.7]
TCI [4–6] 1396 7.2% [5.9–8.6] 10.7% [9.1–12.4] 17.1% [15.1–19.3] 22% [19.7–24.4]
p value <0.0001 0.0002 0.03 <0.0001
RIC 1714 3.9% [3–4.9] 7.2% [6–8.5] 14% [12.3–15.8] 27.6% [25.4–29.8]
MAC 2144 6.2% [5.3–7.3] 9.6% [8.4–10.9] 15.8% [14.2–17.5] 22.9% [21–24.8]
p value 0.001 0.006 0.20 0.0002
55–65 years
TCI [1,2] 2105 3.3% [2.6–4.2] 7.2% [6.1–8.3] 15.7% [14.1–17.4] 30.9% [28.9–33]
TCI [2.5–3.5] 1927 7.4% [6.3–8.6] 12.4% [10.9–13.9] 20.8% [18.9–22.8] 26% [23.9–28.1]
TCI [4–6] 365 9.3% [6.6–12.6] 17.1% [13.4–21.2] 24.7% [20.2–29.5] 22.8% [18.4–27.4]
p value <0.0001 <0.0001 <0.0001 <0.0001
RIC 3338 4.9% [4.2–5.7] 9% [8–10] 17.6% [16.3–19] 28.6% [26.9–30.2]
MAC 1059 7.9% [6.3–9.6] 14.3% [12.2–16.5] 22.1% [19.5–24.8] 26.6% [23.8–29.4]
p value 0.0002 <0.0001 0.004 0.17
Values are given in % and [range].
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Fig. 2 Early nonrelapse mortality (NRM) according to TCI. a Early NRM in the subgroup of patients aged 45–55 years at transplant (n=
3858). b Early NRM in patients aged between 55 and 65 years (n= 4397).
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The TCI proved to be the most important determinant of
early and overall NRM with multivariable analysis, also
when adjusted for HCT-CI in nearly 4000 cases with
available data. The risk groups based on the TCI scores were
more evenly distributed and provided better discrimination
(based on the c-statistic) of NRM than the risk groups
defined by the RIC/MAC classification. This improvement is
probably attributed to the use of weighted scores based on
the threshold of myeloablative doses, which subdivided the
MAC group by placing 19% of the “borderline” MAC
regimens in the intermediate TCI group. Moreover, the
assignment of weighted scores for all components probably
captured a group of patients who received an “intensified”
RIC. Indeed, about 15% of the RIC regimens incorporated at
least three components instead of the commonly used two in
“standard” RIC regimens (Supplementary Table 1).
TCI was highly predictive for relapse risk and performed
better than RIC/MAC. The correlation between regimen
intensity and relapse in AML has been documented in many
retrospective reports [18, 19] and prospective studies
[20–22]. Not surprisingly, both TCI and RIC/MAC group-
ing had a weak association with LFS and OS on multi-
variate analysis. This reflects the contradictory effect of
conditioning intensity in NRM and relapse and the strong
likelihood of selection bias in the choice of conditioning.
Two prospective randomized trials comparing MAC versus
RIC in AML [20] and secondary AML or MDS [21] found
no significant difference in LFS and OS. Another
randomized trial suggested a better OS in AML patients
treated with MAC versus RIC, however, data closure in this
study was at 18-months post-transplant and thus additional
follow-up is warranted until a definitive conclusion can be
done [22].
A large component of the improvement in intensity
reclassification achieved by the TCI is that it identifies a
distinct subgroup of RIC and MAC regimens that had
identical outcomes in all aspects (Table 6). This inter-
mediate TCI [2.5–3.5] group probably captured the so
called “reduced toxicity conditioning” regimens that were
specifically designed by various transplant groups in a way
to optimize dose intensity while safely minimizing NRM
and which were not readily amenable to the earlier RIC/
MAC approach [7]. This is illustrated in Fig. 1b which gives
examples of some very commonly used “reduced toxicity
conditioning” regimens, such as fludarabine-based regimens
which incorporate two alkylating agents in sub-
myeloablative doses (e.g., Fludarabine–BCNU–Melphalan
[9], Thiotepa–Busuplhan–Fludarabine [23]), the sequential
conditioning regimens (e.g., FLAMSA) [10] or the
Busulfan–Fludarabine regimen which has lower toxicity
when directly compared with classical MAC
Busulfan–Cyclophosphamide combination [24].
There are limitations in this study. First, weightings were
based on scientific and clinical background and not on sta-
tistical consideration. However, we used RIC/MAC con-
sensus rules to define dose levels and integer weights for
Table 6 The intermediate TCI [2.5–3.5] group.
RIC/MAC N NRM @ day 100 NRM @ day 180 NRM Relapse LFS OS
RIC 1819 6.9% [5.8–8.1] 10.9% [9.5–12.4] 18.7% [16.9–20.6] 24.5% [22.4–26.6] 56.8% [54.4–59.3] 62.2% [59.8–64.6]
MAC 1552 5.7% [4.6–6.9] 10.1% [8.7–11.7] 17% [15.0–19.0] 26.2% [23.9–28.5] 56.8% [54.2–59.5] 61.2% [58.6–63.8]
p value 0.15 0.43 0.02 0.05 0.92 0.62
Values are given in % and [range].
Table 5 Validation of TCI versus RIC/MAC on 200 bootstrap samples.
NRM @ day 100 NRM @ day 180 NRM Relapse LFS OS
Cox (HR, 95% CI)
TCI [1,2] 1 (reference) 1 1 1 1 1
TCI [2.5–3.5] 1.77 (1.38–2.27) 1.63 (1.36–1.97) 1.27 (1.14–1.45) 0.79 (0.71–0.87) 0.94 (0.87–1.03) 1.02 (0.94–1.09)
TCI [4–6] 2.97 (2.2–4.06) 2.36 (1.88–2.94) 1.51 (1.28–1.77) 0.7 (0.63–0.82) 0.95 (0.85–1.07) 1 (0.9–1.12)
p, TCI [2.5–3.5] vs [1,2] 0.005 0.01 0.03 0.01 0.64 0.94
p, TCI [4–6] vs [1,2] 0.005 0.005 0.005 0.005 0.79 0.95
C-statistic (95% CI)
TCI grouping 0.6747 0.6416 0.6201 0.5861 0.5604 0.5779
(0.6729–0.6764) (0.6401–0.6430) (0.6190–0.6212) (0.5852–0.5869) (0.5597–0.5611) (0.5771–0.5787)
RIC/MAC 0.6436 0.6219 0.6113 0.5784 0.5595 0.5713
(0.6419–0.6454) (0.6205–0.6234) (0.6102–0.6124) (0.5776–0.5793) (0.5588–0.5602) (0.5705–0.5721)
p value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.007
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most components, and thus it is likely that the TCI has at
least the same validity as the original RIC/MAC scheme.
Second, we have attempted to minimize the possible lim-
itations inherent in retrospective registry-based studies by
studying a large patient cohort, by double-checking the RIC/
MAC information and by using early NRM as primary
endpoint for estimating the impact of TCI, an outcome
which is very reliable documented in registry databases and
is not influenced by events that evolve over time (e.g.,
chronic GVHD). Third, beyond the internal bootstrap vali-
dation used in this study an external validation in a truly
distinct database or, even better, prospectively is warranted
[25, 26]. Fourth, to confirm generalizability it is necessary to
determine in future studies whether the model continues to
perform as well across different diseases (except AML) and
disease risk groups. However, since NRM is not influenced
by disease risk [16], it is very likely that the predictive
ability of TCI for early NRM applies to the entire spectrum
of HCT patients. Fifth, the applicability and the value of TCI
in other age groups, e.g., pediatrics, should be further
evaluated. Sixth, one must keep in mind that drugs have
differing mechanisms of actions and toxicity profiles and
therefore both NRM and relapse may be besides intensity
gradient also influenced in a regimen-specific manner
[18, 27]. The integer weights are given arbitrarily and do not
measure such “qualitative” factors (e.g., drug–drug interac-
tions, drugs given in targeted doses, pharmacokinetics). In
addition, the current TCI does not account for antisera used
for GVHD prevention or for drugs given after graft infusion,
such as post-transplant cyclophosphamide [28]. Future pro-
spective trials including such aspects and the use of machine
learning algorithms will be important to strengthen and
recalibrate this index [29]. The prototype TCI presented here
provides the baseline against which the predictive ability of
these refined indices can be compared.
We propose the TCI scheme as a valid improvement on
the RIC/MAC stratification system to define and measure
transplant conditioning intensity. Compared with RIC/
MAC, TCI provided better assessment of NRM and relapse
risk; provided finer categorization and better discriminating
ability; accounts for new regimens that were not readily
amenable to the RIC/MAC approach; could be easily and
precisely calculated for any patient; and could capture
subtle regimen intensity variations (e.g., when reducing the
dose of a component due to patient-related factors). TCI
was effective in predicting NRM and relapse independently
of other validated prognostic factors and thus TCI may be
used in association with HCT-CI, DRI and donor type to
assess transplant outcome. In every day clinical practice
TCI may help to optimize conditioning intensity, thereby
providing personalized treatment. We hope that future
research will further confirm and validate the TCI in dif-
ferent patient groups, will refine the integer weights of each
agent and modify the TCI to improve its sensitivity and
specificity. This TCI concept may readily accommodate
new conditioning regimen components, rendering it future-
proof. We anticipate that the TCI scheme has the potential
to become a universal, well-defined and standard termi-
nology for use in registry databases, in the literature and in
clinical trials, thus facilitating comparative studies.
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